Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 7Mastocytosis, Systemic 5Recurrence 3Leukemia, Mast-Cell 2Glioma 2Sarcoma 1Neoplasms 1Mastocytosis 1Glioblastoma 1GIST 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 32Radiotherapy 11Bevacizumab 10Surgical Procedures, Operative 7IL13-PE38 7TIC10 compound 6Lomustine 6Carboplatin 6Radiation 5Chlorotoxin 5vorasidenib 4trametinib 4dabrafenib 4Valacyclovir 4OKN 007 4Flucytosine 4Dianhydrogalactitol 4Cyclophosphamide 4vocimagene amiretrorepvec 3abemaciclib 3Paclitaxel 3Nivolumab 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3CLR1404 3trans-sodium crocetinate 2pembrolizumab 2olutasidenib 2marizomib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Glioma × avapritinib × Clear all
NCT04773782 2026-01-13

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Blueprint Medicines Corporation

Phase 1/2 Completed
29 enrolled
CNS

Glioma, Recurrence, Central Nervous System Neoplasms

NCT04714086 2024-10-24

Expanded Access Program for Avapritinib

Blueprint Medicines Corporation

No longer available
CNSGastrointestinalSarcoma

Glioma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡